



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Continuation of 10/224,761
				Filing Date	November 21, 2003
				First Named Inventor	Solomon S. Steiner
				Group Art Unit	
Examiner Name					
Sheet	1	of	2	Attorney Docket Number	PDT 120/121 DIV CON

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JHAA		5,352,461		Feldstein et al.	10-04-1994	
		5,503,852		Steiner et al.	04-02-1996	
		5,547,929		Anderson Jr. et al.	08-20-1996	
		5,888,477		Gonda et al.	03-30-1999	
		5,976,569		Milstein	11-02-1999	
		6,071,497		Steiner et al.	06-06-2000	
		6,331,318		Milstein	12-18-2001	
		6,395,774		Milstein	05-28-2002	
JHAA		6,428,771		Steiner, et al.	08-06-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
JHAA		PCT	WO 96/36314		Pharmaceutical Discovery Corporation	11-21-1996		
JHAA		PCT	WO 99/52506		Aventis Research & Technologies	10-21-1999		
JHAA		EP	0 220 958		Eli Lilly and Company	05-06-1987		

Abstr.
Only

Examine Signature	James Henry Alstrum-Acevedo	Date Considered	05/12/2006
-------------------	-----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/DAA (10-88)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	Continuation of 10/224,761		
		Filing Date	November 21, 2003		
		First Named Inventor	Solomon S. Steiner		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	PDT 120/121 DIV CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JHAA		CERASI, et al., "Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study," <i>Diabetes</i> 21(4): 224-34 (1972).	
		GUPTA, et al., "Contemporary approaches in aerosolized drug delivery to the lung," <i>Journal of Controlled Release</i> 17:129-148 (1991).	
		KATCHALSKI, et al., "Synthesis of lysine anhydride," <i>J. Amer. Chem. Soc.</i> 68: 879-80 (1946).	
		KOPPLE, et al., "A convenient synthesis of 2,5-piperazinediones," <i>J. Org. Chem.</i> 33(2): 862-64 (1968).	
		LEAHY, "Beta-cell dysfunction in type II diabetes mellitus," <i>Curr. Opin. Endocrinol. Diabetes</i> 2(4): 300-306 (1995).	
		LIAN, et al., "A self-complementary, self-assembling microsphere system: application for intravenous delivery of the antiepileptic and neuroprotectant compound felbamate," <i>J Pharm Sci</i> 89:867-875 (2000).	
		PFEIFFER, "Insulin secretion in diabetes mellitus," <i>Am. J. Med.</i> 70(3): 579-88 (1981).	
JHAA		POLONSKY, et al., "Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus," <i>N. England J. Med.</i> 318(19): 1231-39 (1988).	

Examiner's Signature	James Henry Alstrum-Acevedo	Date Considered	05/12/2006
----------------------	-----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.